期刊文献+

超声影像组学标签对乳腺癌HER-2状态的预测价值 被引量:2

Ultrasound-based radiomics to predict HER-2 status in breast cancer
原文传递
导出
摘要 目的探讨基于超声的影像组学标签在术前预测乳腺癌HER-2状态中的价值。方法回顾性收集230例浸润性乳腺癌患者的临床资料和术前超声图像。按超声检查时间顺序,将患者分为训练组(n=115)和验证组(n=115)。通过Image J软件沿肿瘤边界手动勾画超声图像中的病灶区域,使用Pyradiomics从每个病灶区域中提取1 820个特征,采用3种统计学方法筛选特征,利用逻辑回归模型构建超声影像组学标签。采用受试工作特征曲线(ROC)、校准曲线及决策曲线等评估超声影像组学标签预测HER-2状态的效能和价值。结果最终选取9个关键影像特征用于构建超声影像组学标签。该标签在训练组和验证组中的ROC曲线下面积分别为0.82[95%CI(0.74,0.90)]、0.81[95%CI(0.72,0.89)]。校准曲线显示该标签在训练集和验证集中均具有较好的校准度。结论基于超声的影像组学标签在术前预测乳腺癌HER-2状态中具有重要价值。 Objective To explore the value of a radiomics model based on ultrasound imaging in predicting the HER-2 status of breast cancer prior to surgery. Methods A total of 230 patients with invasive breast cancer were retrospectively analyzed, all the patients underwent preoperative breast ultrasound examination. According to the order of examination time, the patients were categorized into training group(n=115) and validation group(n=115). Image J software was used to manually delineate the lesion area in the ultrasound image along the tumor boundary. Pyradiomics was used to extract 1 820 features from each lesion area, and three statistical methods were used to screen features. A logistic regression model was used to construct ultrasound imaging radiomics model. The receive operating characteristic curve(ROC), calibration curve and decision curve were used to evaluate the performance and value of ultrasound imaging radiomics model in predicting HER-2 status. Results Nine key image features were identified to construct ultrasound imaging radiomics model. The area of under the ROC curve of the model in the training group and the validation group were 0.82(95%CI 0.74 to 0.90) and 0.81(95%CI 0.72 to 0.89), respectively. The calibration curve showed that the model had a good calibration in both the training and validation groups. Conclusions Ultrasound-based imaging radiomics model is of significant value in predicting the HER-2 status of breast cancer prior to surgery.
作者 王瑛 陈英格 叶素敏 陈东 吴磊 刘再毅 刘敏 WANG Ying;CHEN Yingge;YE Sumin;CHEN Dong;WU Lei;LIU Zaiyi;LIU Min(Department of Ultrasound,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,P.R.China;Department of Ultrasound,the Third Affiliated Hospital of Kunming Medical University I Yunnan Cancer Hospital,Kunming 650118,P.R.China;Department of Radiology,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,P.R.China;Department of Ultrasound,Sun Yat-Sen University Cancer Center/State Key Laboratory of Oncology in South China/Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,P.R.China)
出处 《中国循证医学杂志》 CSCD 北大核心 2021年第3期271-275,共5页 Chinese Journal of Evidence-based Medicine
基金 国家重点研发计划项目(编号:2017YFC1309100)。
关键词 超声 影像组学 乳腺癌 人表皮生长因子受体 决策曲线 Ultrasound Radiomics Breast cancer HER-2 Decision curve
  • 相关文献

参考文献6

二级参考文献45

  • 1Wolff AC, Hammond MEH,Hicks DG, et al. Recommendationsfor human epidermal growth factor receptor 2 testing in breastcancer: American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update. ArchPathol Lab Med, 2013,138(2) : 241-256. DOI: 10. 5858/arpa.2013-0953-SA.
  • 2Fabi A, Di Benedetto A, Metro G,et al. HER2 protein and genevariation between primary and metastaticbreast cancer :significance and impact on patient care. Clin Cancer Res, 2011,17(7) : 2055-2064. DOI: 10.1158/1078-0432. CCR-10-1920.
  • 3Robert N,Leylan-Jones B, Asmar L, et al. Randomized phase Idstudy of trastuzumab, paclitaxel, and carboplatin compared withtrastuzumab and paclitaxel in women with HER-2 -overexpressingmetastatic breast cancer[ J]. J Clin Oncol, 2006, 24(18) : 2786-2792.
  • 4Wardley AM, Pivot X,Morales-Vasquez F, et al. Randomizedphase II trial of first-line trastuzumab plus docetaxel andcapecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [ J ]. J Clin Oncol,2010,28(6): 976-983. DOI: 10.1200/JC0.2008.21.6531.
  • 5Andersson M, Lidbrink E, Bjerre K, et al. Phase HI randomizedstudy comparing docetaxel plus trastuzumab with vinorelbine plustrastuzumab as first-line therapy of metastatic or locally advancedhuman epidermal growth factor receptor 2-positive breast cancer:The HERNATA study [J]. J Clin Oncol, 2011, 29 ( 3 ) : 264-271. DOI: 10.12OO/JCO. 2010. 30. 8213.
  • 6Schaller G, Fuchs I, Gonsch T,et al. Phase U Study ofCapecitabine Plus Trastuzumab in Human Epidermal GrowthFactor Receptor 2 -Overexpressing Metastatic Breast CancerPretreated With Anthracyclines or Taxanes [ J ]. J Clin Oncol,2007, 25(22) : 3246-3250.
  • 7Yardley DA, Burris HA, Hanson S, et al. Weekly gemcitabineand trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer[ J]. Clin Breast Cancer,2009 , 9(3) : 178-183. DOI: 10.3816/CBC.2009. n. 029.
  • 8Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab,and docetaxel in HER2-positive metastatic breast cancer [ J ] . NEngl J Med, 2015,372 ( 8 ) : 724-734. DOI: 10. 1056/NEJMoal413513.
  • 9Kaufman B, Mackey JR,Clemens MR,et al. Trastuzumab plusanastrozole versus anastrozole alone for the treatment ofpostmenopausal women with human epidermal growth factorreceptor 2-positive, hormone receptor-positive metastatic breastcancer : Results from the randomized phase ]H TAnDEM study[J]. J Clin Oncol, 2009, 27(33) : 5529-5537. DOI: 10. 1200/JCO.2008.20.6847.
  • 10Johnston S, Pippen J, Pivot X, et al. Lapatinib combined withletrozole versus letrozole and placebo as first-line therapy forpostmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol, 2009, 27(33) : 5538-5546. 10.1200/jc0.2009.23.3734.

共引文献283

同被引文献20

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部